# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 551-560 of 561 results.
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy
Status: Recruiting
Last Changed: Feb 21, 2020
First Received: Jan 13, 2020
Disease(s): Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
Intervention(s): CT-RD06
Locations: The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou, Zhejiang, China
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Status: Recruiting
Last Changed: Jul 08, 2020
First Received: Sep 14, 2018
Disease(s): Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Intervention(s): TG-1701, Umbralisib, Ublituximab
Locations: TG Therapeutics Investigational Trial Site, Adelaide, Australia
TG Therapeutics Investigational Trial Site, Fitzroy, Australia
St. Vincent's Hospital, Melbourne, Australia
TG Therapeutics Investigational Trial Site, Nedlands, Australia
TG Therapeutics Investigational Trial Site, Kraków, Poland
... and 3 other locations.
A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies
Status: Recruiting
Last Changed: Jun 25, 2019
First Received: Mar 16, 2016
Disease(s): Leukemia, Lymphoma
Intervention(s): Anti-CD20-CAR-transduced T cells
Locations: Southwest Hospital of Third Millitary Medical University, Chongqing, Chongqing, China
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
Status: Recruiting
Last Changed: Apr 26, 2018
First Received: Aug 25, 2017
Disease(s): Leukemia, Lymphoma
Intervention(s): Anti-CD22-CAR-transduced T cells
Locations: Fengtai District, Beijing, Beijing, China
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Status: Recruiting
Last Changed: Jun 25, 2019
First Received: Oct 17, 2016
Disease(s): Leukemia, Lymphoma
Intervention(s): Anti-CD22-CAR-transduced T cells
Locations: Southwest Hospital of Third Millitary Medical University, Chongqing, Chongqing, China
A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
Status: Recruiting
Last Changed: Jun 20, 2017
First Received: Jun 19, 2017
Disease(s): Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Intervention(s): Drugs and anti-CD19 CAR transduced T cells
Locations: Department of Hematology, Dongguan People's Hospital, Dongguan, Guangdong, China
Department of Hematology, the First People's Hospital of Foshan, Foshan, Guangdong, China
Department of Hematology, Guangzhou First People's Hospital, Guangzhou, Guangdong, China
Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
Department of Hematology,the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
... and 1 other locations.
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
Status: Recruiting
Last Changed: Jul 08, 2020
First Received: Sep 19, 2018
Disease(s): Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma, ACUTE LYMPHOBLASTIC LEUKEMIA
Intervention(s): inotuzumab ozogamicin-dose level 2, Inotuzumab ozogamicin-dose level 1
Locations: Keck Hospital of USC-Norris Comprehensive Cancer Center (HC3), Los Angeles, California, United States
Keck Hospital of USC, Los Angeles, California, United States
LAC+USC Medical Center, Los Angeles, California, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Children's Hospital of Orange County, Orange, California, United States
... and 57 other locations.
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Status: Recruiting
Last Changed: Jan 18, 2020
First Received: Jan 30, 2014
Disease(s): Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL
Intervention(s): CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T Cells - dose escalation 1
Locations: Houston Methodist Hospital, Houston, Texas, United States
Texas Children's Hospital, Houston, Texas, United States
CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy
Status: Recruiting
Last Changed: Dec 03, 2018
First Received: Sep 02, 2015
Disease(s): Leukemia, Lymphoma
Intervention(s): CD19-directed CAR-T cells
Locations: Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Status: Recruiting
Last Changed: Jul 27, 2020
First Received: Jun 19, 2019
Disease(s): Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Intervention(s): Etoposide, Doxorubicin, Vincristine, Prednisone, Cyclophosphamide, Inotuzumab Ozogamicin
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States